The long-delayed promise of the microbiome, with Sam Possemiers
Автор: pharmaphorum media limited
Загружено: 2026-02-06
Просмотров: 5
Описание:
The human microbiome is an area of tremendous therapeutic potential, but one where not much progress has been made, with only a pair of C. diff. treatments currently approved by the FDA.
Sam Possemiers, CEO of MRM Health, believes that the space is finally coming into maturity. At his own company, that’s in the form of a drug for ulcerative colitis that he hopes to see complete its phase 3 trial in late 2027.
In an interview with pharmaphorum Editor in Chief Jonah Comstock conducted at the Informa Biotech Showcase in San Francisco last month, Possemiers describes how success with the microbiome depends on identifying specific bacteria with therapeutic benefit, then manufacturing and delivering those bacteria in a scalable way. That’s what will turn microbiome therapeutics into serious drugs.
Check out the video for a discussion of the microbiome space, an update on MRM Health’s work, and some reflections on the mood at JPM 2026.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
